EUVIMEDEUVIMED entdecken
Multizentrische Studie

Characteristics of Coronary Atherosclerosis Related to Plaque Burden Regression During Treatment With Alirocumab: The ARCHITECT Study

Leopoldo Pérez de Isla iD, Jose L Díaz-Díaz iD, Manuel J Romero iD, Ovidio Muñiz-Grijalvo iD, Juan D Mediavilla iD, Rosa Argüeso iD, Raimundo de Andrés iD, Francisco Fuentes iD, Juan F Sánchez Muñoz-Torrero iD, Patricia Rubio iD, Pilar Álvarez-Baños, Dolores Mañas und 4 weitere

Circulation: Cardiovascular Imaging · 2024

DOI: 10.1161/circimaging.123.016206 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Circulation: Cardiovascular Imaging, 2024. Verfasst von Leopoldo Pérez de Isla und 15 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Department, Clinico San Carlos University Hospital, Madrid, Spain (L.P.d.I.). Hauptthemen laut MEDLINE: Coronary Artery Disease, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Plaque, Atherosclerotic, Hypercholesterolemia. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Intensive lipid-lowering therapy may induce coronary atherosclerosis regression. Nevertheless, the factors underlying the effect of lipid-lowering therapy on disease regression remain poorly characterized. Our aim was to determine which characteristics of atherosclerotic plaque are associated with a greater reduction in coronary plaque burden (PB) after treatment with alirocumab in patients with familial hypercholesterolemia. METHODS: The ARCHITECT study (Effect of Alirocumab on Atherosclerotic Plaque Volume, Architecture and Composition) is a phase IV, open-label, multicenter, single-arm clinical trial to assess the effect of the treatment with alirocumab for 78 weeks on the coronary atherosclerotic PB and its characteristics in subjects with familial hypercholesterolemia without clinical atherosclerotic cardiovascular disease. Participants underwent a coronary computed tomographic angiography at baseline and a final one at 78 weeks. Every patient received alirocumab 150 mg subcutaneously every 14 days in addition to high-intensity statin therapy. RESULTS: One hundred and four patients were enrolled. Median age was 53.3 (46.2–59.4) years and 54 were women (51.9%). The global coronary PB changed from 34.6% (32.5%–36.8%) at entry to 30.4% (27.4%–33.4%) at follow-up, which is −4.6% (−7.7% to −1.9%; P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Coronary Artery DiseaseHydroxymethylglutaryl-CoA Reductase InhibitorsPlaque, AtheroscleroticHypercholesterolemiaHyperlipoproteinemia Type IIAntibodies, Monoclonal, HumanizedHumansFemaleMiddle AgedMaleCholesterol, LDLTreatment Outcome

Stichwörter der Autor:innen

atherosclerosischolesterolcoronary vessels

Substanzen

alirocumabHydroxymethylglutaryl-CoA Reductase InhibitorsCholesterol, LDLAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Cardiology Department, Clinico San Carlos University Hospital, Madrid, Spain (L.P.d.I.).
  • Internal Medicine Department, Hospital Abente y Lago, A Coruña, Spain (J.L.D.-D.).
  • Internal Medicine Department, Hospital Infanta Elena, Huelva, Spain (M.J.R.).
  • Internal Medicine Department, Hospital Virgen del Rocío, Sevilla, Spain (O.M.-G.).
  • Internal Medicine Department, Hospital Universitario Virgen de las Nieves, Granada, Spain (J.D.M.).
  • Endocrinology Department, Hospital Universitario Lucus Augusti, Lugo, Spain (R.A.).

ORCID-Profile: Leopoldo Pérez de Isla, Jose L Díaz-Díaz, Manuel J Romero, Ovidio Muñiz-Grijalvo, Juan D Mediavilla, Rosa Argüeso, Raimundo de Andrés, Francisco Fuentes, Juan F Sánchez Muñoz-Torrero, Patricia Rubio, Lorena Suárez Gutierrez

Zitieren

APA

Pérez de Isla, L., Díaz-Díaz, J. L., Romero, M. J., Muñiz-Grijalvo, O., Mediavilla, J. D., Argüeso, R., de Andrés, R., Fuentes, F., Sánchez Muñoz-Torrero, J. F., Rubio, P., Álvarez-Baños, P., Mañas, D., Suárez Gutierrez, L., Saltijeral Cerezo, A., Mata, P., & SAFEHEART Investigators (2024). Characteristics of Coronary Atherosclerosis Related to Plaque Burden Regression During Treatment With Alirocumab: The ARCHITECT Study. Circulation: Cardiovascular Imaging. https://doi.org/10.1161/circimaging.123.016206

Vancouver

Pérez de Isla L, Díaz-Díaz JL, Romero MJ, Muñiz-Grijalvo O, Mediavilla JD, Argüeso R, et al. Characteristics of Coronary Atherosclerosis Related to Plaque Burden Regression During Treatment With Alirocumab: The ARCHITECT Study. Circulation: Cardiovascular Imaging. 2024. doi:10.1161/circimaging.123.016206

BibTeX
@article{PrezdeIsla2024,
  author = {Pérez de Isla, Leopoldo and Díaz-Díaz, Jose L and Romero, Manuel J and Muñiz-Grijalvo, Ovidio and Mediavilla, Juan D and Argüeso, Rosa and de Andrés, Raimundo and Fuentes, Francisco and Sánchez Muñoz-Torrero, Juan F and Rubio, Patricia and Álvarez-Baños, Pilar and Mañas, Dolores and Suárez Gutierrez, Lorena and Saltijeral Cerezo, Adriana and Mata, Pedro and SAFEHEART Investigators, SAFEHEART Investigators},
  title = {Characteristics of Coronary Atherosclerosis Related to Plaque Burden Regression During Treatment With Alirocumab: The ARCHITECT Study},
  journal = {Circulation: Cardiovascular Imaging},
  year = {2024},
  doi = {10.1161/circimaging.123.016206}
}
Kostenlos starten →